Work

Oral weekly MLN9708, an investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma (MM): A phase I/II study.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.8033

Authors: Paul Gerard Guy Richardson, Jesus G. Berdeja, Ruben Niesvizky, Sagar Lonial, Vivek Roy, Parameswaran Hari, Deborah Berg, Guohui Liu, Neeraj Gupta, Alessandra Di Bacco, Ai-Min Hui, Shaji Kumar

Institutions: Dana-Farber Cancer Institute, Sarah Cannon, NewYork–Presbyterian Hospital, Cornell University, Emory University, Winship Cancer Institute, Mayo Clinic in Florida, Medical College of Wisconsin, Takeda Oncology (United States), Mayo Clinic

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2601289800

Cites:

Cited by: 26

Related to: 10